Association between Polycystic Ovary Syndrome and Breast Cancer: A Review

Main Article Content

Kwan Jia Ni
Daryl Tan Shuang Shuang
Nisha Angela Dominic
Valliammai Jayanthi Thirunavuk Arasoo


Aims: Polycystic ovary syndrome (PCOS) is a common endocrine disorder seen in women of reproductive age. The hormonal profile and comorbidities seen in women with PCOS like obesity and diabetes are some of the main risk factors of breast cancer. The aim of this review is to investigate the plausible association between PCOS and breast cancer. This review focuses on the epidemiological evidence, association of PCOS-related symptoms and PCOS medications on the incidence of breast cancer.

Methodology: A comprehensive literature search using Ovid MEDLINE, Google Scholar and PubMed was performed to identify epidemiologic studies that have been published in the last 10 years (from 2010 to 25th June 2020) that reported on the association between PCOS and breast cancer. The following keywords were used: polycystic ovary syndrome, breast cancer and breast neoplasms.

Results: Most of the epidemiological studies did not observe significant association between PCOS and breast cancer. However, evidence shows that elevated androgen levels and estrogen levels are associated with increased risk of estrogen receptor positive breast cancer. In addition, this review found increased breast cancer risk in women with obesity, hyperinsulinemia and low level of sex hormone binding globulin. Unlike metformin and clomiphene citrate, combined hormonal contraceptive, being the first line treatment for PCOS is linked with higher breast cancer risk.

Conclusion: Clinical findings from this review are inconsistent, hence a firm conclusion cannot be made regarding the association between PCOS and breast cancer, emphasizing the need for more prospective studies to be conducted in the future.

Polycystic ovary syndrome, breast cancer, hormonal profile, medications.

Article Details

How to Cite
Ni, K. J., Shuang, D. T. S., Dominic, N. A., & Arasoo, V. J. T. (2020). Association between Polycystic Ovary Syndrome and Breast Cancer: A Review. Asian Research Journal of Gynaecology and Obstetrics, 4(4), 1-12. Retrieved from
Review Article


Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Molecular Metabolism. 2020;35: 100937.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome†‡. Human Reproduction. 2018;33(9):1602-18.

Zawadski J, Dunaif A, Dunaif A GJ, Haseltine FP, Merriam GE. Polycystic ovary syndrome (Current issues in endocrinology and metabolism). Boston. Blackwell Scientific Inc.;1992.

The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41-7.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertility and Sterility. 2009;91(2):456-88.

Secreto G, Girombelli A, Krogh V. Androgen excess in breast cancer development: Implications for prevention and treatment. Endocr Relat Cancer. 2019;26(2):R81-R94.

Shobeiri F, Jenabi E. The association between polycystic ovary syndrome and breast cancer: A meta-analysis. Obstet Gynecol Sci. 2016;59(5):367-72.

Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: A systematic review. Fertility Research and Practice. 2016;2(1):14.

Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748-58.

Yin W, Falconer H, Yin L, Xu L, Ye W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5(1):106-7.

Ding D-C, Chen W, Wang J-H, Lin S-Z. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore). 2018;97(39):e12608.

Shen C-C, Yang AC, Hung J-H, Hu L-Y, Tsai S-J. A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist. 2015;20(1):45-9.

Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study. Gynecologic Oncology. 2015;136(1):99-103.

Brinton LA, Moghissi KS, Westhoff CL, Lamb EJ, Scoccia B. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertility and Sterility. 2010;94(5):1787-92.

Kim J, Mersereau JE, Khankari N, Bradshaw PT, McCullough LE, Cleveland R et al. Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study. Cancer Causes & Control. 2016;27(3):403-14.

Ghasemi N, Mortazavizadeh MR, Khorasani Gerdekoohi A. Frequency of poly cystic ovary syndrome in patients with premenopausal breast cancer. Iran J Reprod Med. 2010;8(2):86-9.

Pinola P, Piltonen TT, Puurunen J, Vanky E, Sundström-Poromaa I, Stener-Victorin E et al. Androgen profile through life in women with polycystic ovary syndrome: A nordic multicenter collaboration study. The Journal of Clinical Endocrinology & Metabolism. 2015;100(9):3400-7.

Sex hormones and risk of breast cancer in premenopausal women: A collaborative reanalysis of individual participant data from seven prospective studies. The Lancet Oncology. 2013;14(10):1009-19.

Schernhammer ES, Sperati F, Razavi P, Agnoli C, Sieri S, Berrino F et al. Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Res. 2013;15(3):R46.

Fourkala E-O, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R et al. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. 2012;19(2):137-47.

Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C et al. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: The multiethnic cohort study. Endocr Relat Cancer. 2010;17(1):125-34.

Fourkala E-O, Blyuss O, Field H, Gunu R, Ryan A, Barth J et al. Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). Steroids. 2016;110:62-9.

Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat. 2013;137(3):883-92.

Trabert B, Bauer DC, Buist DSM, Cauley JA, Falk RT, Geczik AM et al. Association of circulating progesterone with breast cancer risk among postmenopausal women. JAMA Network Open. 2020;3(4):e203645.

Wiebe JP, Zhang G, Welch I, Cadieux-Pitre H-AT. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors. Breast Cancer Res. 2013;15(3): R38.

Dimou NL, Papadimitriou N, Gill D, Christakoudi S, Murphy N, Gunter MJ et al. Sex hormone binding globulin and risk of breast cancer: A Mendelian randomization study. International Journal of Epidemiology. 2019;48(3):807-16.

He XY, Liao YD, Yu S, Zhang Y, Wang R. Sex hormone binding globulin and risk of breast cancer in postmenopausal women: A meta-analysis of prospective studies. Horm Metab Res. 2015;47(7):485-90.

Sebastiani F, Cortesi L, Sant M, Lucarini V, Cirilli C, De Matteis E, et al. Increased incidence of breast cancer in postmenopausal women with high body mass index at the modena screening program. J Breast Cancer. 2016;19(3):283-91.

Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: A secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611-21.

White AJ, Nichols HB, Bradshaw PT, Sandler DP. Overall and central adiposity and breast cancer risk in the sister study. Cancer. 2015;121(20):3700-8.

Gaudet MM, Carter BD, Patel AV, Teras LR, Jacobs EJ, Gapstur SM. Waist circumference, body mass index, and postmenopausal breast cancer incidence in the cancer prevention study-ii nutrition cohort. Cancer Causes & Control. 2014; 25(6):737-45.

Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. obesity reviews. 2013;14(8):665-78.

Shu X, Wu L, Khankari NK, Shu X-O, Wang TJ, Michailidou K et al. Associations of obesity and circulating insulin and glucose with breast cancer risk: A Mendelian randomization analysis. International Journal of Epidemiology. 2018;48(3):795-806.

Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: A meta-analysis. 2012;19(6):793-803.

Sun W, Lu J, Wu S, Bi Y, Mu Y, Zhao J et al. Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women. Am J Cancer Res. 2016;6(10):2334-44.

Bronsveld HK, Jensen V, Vahl P, De Bruin ML, Cornelissen S, Sanders J et al. Diabetes and breast cancer subtypes. PLoS One. 2017;12(1):e0170084.

Bae JM. History of diabetes mellitus and risk of breast cancer in asian women: A meta-epidemiological analysis of population-based cohort studies. J Menopausal Med. 2020;26(1):29-33.

Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine. 2017;377(23):2228-39.

Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: The royal college of general practitioners’ oral contraception study. American Journal of Obstetrics and Gynecology. 2017;216(6): 580.e1-.e9.

Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22(11):1931-43.

Busund M, Bugge NS, Braaten T, Waaseth M, Rylander C, Lund E. Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The norwegian women and cancer study. Int J Cancer. 2018;142(11): 2293-302.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health Initiative randomized trials. JAMA. 2013;310(13):1353-68.

Collaborative group on hormonal factors in Breast C. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-68.

Samson M, Porter N, Orekoya O, Hebert JR, Adams SA, Bennett CL et al. Progestin and breast cancer risk: A systematic review. Breast Cancer Res Treat. 2016;155(1):3-12.

Taheripanah R, Balash F, Anbiaee R, Mahmoodi M, Akbari Sene A. Breast cancer and ovulation induction treatments. Clinical Breast Cancer. 2018;18(5):395-9.

Liat L-G, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecological Endocrinology. 2012;28(10):809-14.

Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Ruggieri D et al. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2014;23(4):584-93.

Reigstad MM, Storeng R, Myklebust TÅ, Oldereid NB, Omland AK, Robsahm TE et al. Cancer risk in women treated with fertility drugs according to parity status—A registry-based cohort study. Cancer Epidemiol Biomarkers Prev. 2017;26(6): 953-62.

Gennari A, Costa M, Puntoni M, Paleari L, De Censi A, Sormani MP et al. Breast cancer incidence after hormonal treatments for infertility: Systematic review and meta-analysis of population-based studies. Breast Cancer Res Treat. 2015; 150(2):405-13.

Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G, Schünemann HJ et al. Association of metformin with breast cancer incidence and mortality in patients with type ii diabetes: A grade-assessed systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2018;27(6):627-35.

Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: New mechanistic insights from epidemiology. Nature Reviews Cancer. 2015;15:484- 98.

Andò S, Gelsomino L, Panza S, Giordano C, Bonofiglio D, Barone I et al. Obesity, leptin and breast cancer: Epidemiological evidence and proposed mechanisms. Cancers (Basel). 2019;11(1):62.

Joshi PA, Goodwin PJ, Khokha R. Progesterone exposure and breast cancer risk: Understanding the biological roots. JAMA Oncol. 2015;1(3):283-5.

Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016;2(1):16057.